Video Library
Proprotein Convertase Subtilisin/Kexin Type 9 in Cholesterol Homeostasis, Inflammation, and Thrombosis Associated with Cardiovascular Diseases
In this video, Prof. Deepak L. Bhatt presents an infographic on Proprotein Convertase Subtilisin/Kexin Type 9 in Cholesterol Homeostasis, Inflammation, and Thrombosis Associated with Cardiovascular Diseases – an overview of molecular functions and therapeutic strategies.
Prof. Deepak L. Bhatt
First published: September 10, 2024
Video Library
European Society of Cardiology (ESC) Congress highlights 2024
Video highlights from the European Society of Cardiology (ESC) Congress 2024, taking place in London from August 30 to September 2. Featuring faculty members Prof Stephen Nicholls, Prof Deepak Bhatt and Prof Yi-Heng Li, these clips provide invaluable insights and updates on cardiovascular research from ESC Congress 2024.
Prof Stephen Nicholls, Prof Yi-Heng Li
First published: August 30, 2024
Video Library
Therapeutic Management of Dyslipidaemia
In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the therapeutic management of dyslipidaemia. Dyslipidaemia, a key risk factor for cardiovascular diseases, is conventionally managed through therapies targeting lipoproteins such as LDL, Lp(a), IDL + VLDL through small-molecule therapeutics. Despite their effectiveness, off-target events and poor patient compliance often pose significant challenges. Hence novel therapeutics, such as small interfering RNAs, antisense oligonucleotides, and monoclonal antibodies have been developed. These advancements highlight a significant step forward in the management of dyslipidaemia. Prof. Cannon emphasizes these main points in the video, aiming to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.
Prof. Christopher Cannon
First published: August 1, 2024
Video Library
World Heart Federation Roadmap
In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the World Heart Foundation’s Cholesterol Roadmap (2022) for the management and prevention of atherosclerotic cardiovascular disease (ASCVD). He discusses various approaches for ASCVD prevention, emphasizes regional differences in adherence to ASCVD treatment guidelines, and highlights barriers to effective risk management. This roadmap offers a scientifically sound foundation for policymakers to implement changes aimed at reducing the burden of ASCVD.
Prof. Christopher Cannon
First published: August 1, 2024
Video Library
Advancing Treatment for Atherosclerotic Cardiovascular Disease: Drug Therapies and Innovative Surgical Interventions
This video explores advancements in treating Atherosclerotic Cardiovascular Disease (ASCVD), highlighting novel drugs like olezarsen and inclisiran, surgical interventions for aortic stenosis, and the efficacy of percutaneous coronary interventions (PCIs). It encapsulates findings from the American College of Cardiology’s 73rd annual expo.
First published: July 3, 2024
Running time: 21 minutes, 42 seconds
01.53 Cardiovascular kidney metabolic syndrome
02.44 Subclinical inflammation and cardiovascular risk
03.38 Latest data from EAS: Semaglutide, C-reactive
protein level and cardiovascular outcomes05.56 Targeted anti-inflammatory therapies for CVD reduction
07.08 Effect of lipid lowering treatments on CRP levels
08.42 Facets of inflammation in acute MI
10.53 Genetic risk, LDL, lifestyle modifications and genetic tests
14.45 Cholesterol, plasma triglycerides, cardiovascular
and non-cardiovascular mortality16.01 Novel tools to reduce triglyceride levels –
Zodasiran and Plozasiran17.42 Lipoprotein(a)- a risk factor for ASCVD
20.44 Lp(a) lowering therapies
Video Library
Highlights from 92nd European Atherosclerosis Society Congress – Part 1
Prof. Lale Tokgozoglu summarizes the key highlights from the EAS Congress 2024 focusing on inflammation, LDL-C, Lp(a) and cardiovascular outcomes.
Prof. Stephen Nicholls and Prof. Lale Tokgozoglu
First published: June 28, 2024
Running time: 18 minutes, 28 seconds
00.43 Effect of early initiation of PCSK9 inhibition on LDL-C in
patients with acute coronary syndrome02.15 Plaque imaging techniques
03.03 Reduction of LDL-C and plaque progression with statins
04.50 Effect of evolocumab on progression of coronary disease
in statin-treated patients10.37 Effect of adding alirocumab to high-intensity statin
therapy in patients with myocardial infarction11.45 Benefits of PCSK9 inhibitors in CV outcomes trials
13.32 Effect of bempedoic acid alone and in combination with
ezetimibe in hypercholesterolemic patients with or without statin intolerance17.11 Summary of lipid lowering strategies
Video Library
Highlights from 92nd European Atherosclerosis Society Congress – Part 2
Prof. Stephen Nicholls delves into significant findings from the EAS, focusing on plaque and bempedoic acid.
Prof. Stephen Nicholls
First published: June 28, 2024
Video Library
Highlights from 92nd European Atherosclerosis Society Congress – Q&A
Prof. Lale Tokgozoglu and Prof. Stephen Nicholls address audience questions in an interactive Q&A session following the key highlights from the EAS Congress 2024.
Prof. Stephen Nicholls and Prof. Lale Tokgozoglu
First published: June 28, 2024
Video Library
Highlights of “Lower, Longer, Sooner, Earlier, and Younger”: Do we have enough evidence?
This video summarizes Prof. Chiang’s discussion on ASCVD in context of cumulated LDL exposure, and the different stages of secondary prevention and how starting to manage the disease at a younger age or earlier stage is beneficial. The full discussion can be viewed here.
Prof. Chern-En Chiang
First published: June 28, 2024